Contribute Try STAT+ Today

In a little-noticed move, a Commerce Department unit has proposed a new rule that would prevent the federal government from using a controversial legal provision known as “march-in rights” to combat the high prices of products developed with taxpayer dollars. And if adopted, the change may rob Americans of a tool that could be used to lower prescription drug costs, according to consumer advocates.

Under federal law, a government agency that funds private research — such as the National Institutes of Health — can require a company to license its patent to another party in order to “alleviate health and safety needs which are not being reasonably satisfied.” An agency can also do so when the benefits of a product, such as a medicine, are not available on “reasonable terms.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • The huge issue I have with this marvh in rights concept is we hy shouldn’t it apply uniquely to the drug industry and worse yet yo Gilead’s remedesivir to try to control prices?

    Why won’t it apply to the GPS msnnufacturers to compel 50%,, price cut for their GPS devices? Didn’t the fund mantal technology come from the US Military? What about NCI’s role in cancer research? Won’t it great to be abkev to cut all chemotherapeutic agents and drugs with NCI participation in research by say 25%?

Comments are closed.